VNP40101M

Drug name

VNP40101M

Brand name(s)/Manufacturer(s)

Cloretazine; Manufacturer: Vion Pharmaceuticals, Inc.

How the Drug is Given

VNP4010M is given orally.

About the Drug

VNP4010M is a sulfonylhydrazine agent, which works by damaging DNA. It is currently in Phase II of the Food and Drug Adminstration's clinical trials for treatment of myelodysplastic syndromes (MDS) patients.

Side effects

Since VNP40101M is a new drug, investigators are learning about side effects through clinical research studies. Side effects will be posted as published information becomes available.

Special concerns

Since VNP40101M is a new drug, investigators are learning about special concerns through clinical research studies. Special Concerns will be posted as published information becomes available.

More information

Current Clinical Studies

AA&MDSIF: Clinical Trials - www.aamds.org
ClinicalTrials.gov: VNP40101M - www.clinicaltrials.gov 

Medical Information
NIH Medline Bibliography: VNP40101M and MDS - www.pubmed.gov

News Reports
Vion Pharmaceuticals: Vion Presents Cloretazine Data at ASH Annual Meeting -www.vionpharm.com
Yahoo! Finance: Vion holds annual meeting and provides clinical and preclinical development update - www.biz.yahoo.com